These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

526 related items for PubMed ID: 29922758

  • 1. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
    Iacob S, Cerban R, Pietrareanu C, Ester C, Iacob R, Gheorghe C, Popescu I, Gheorghe L.
    J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
    [Abstract] [Full Text] [Related]

  • 2. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.
    Hussar DA, Kavelak HL.
    J Am Pharm Assoc (2003); 2015 Jun; 55(2):216, 219-20, 222. PubMed ID: 25749267
    [No Abstract] [Full Text] [Related]

  • 3. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
    Chen CH, Chen CH, Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, Lu SN, Chien RN, Hung CH, Sheen IS.
    Sci Rep; 2019 May 08; 9(1):7086. PubMed ID: 31068655
    [Abstract] [Full Text] [Related]

  • 4. Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
    Gheorghe L, Iacob S, Curescu M, Brisc C, Cijevschi C, Caruntu F, Stanciu C, Simionov I, Sporea I, Gheorghe C, Iacob R, Arama V, Sirli R, Trifan A.
    J Gastrointestin Liver Dis; 2017 Sep 08; 26(3):275-281. PubMed ID: 28922440
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Pessoa MG, Ramalho-Madruga JV, Alves K, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Correa MC, Ferraz ML, Ferreira PRA, Álvares-da-Silva MR, Coelho HS, Affonso-de-Araújo ES, Furtado J, Parana R, Silva G, Lari SA, Liu L, Tripathi R, Pilot-Matias T, Cohen DE, Shulman NS, Martinelli A.
    Ann Hepatol; 2018 Oct 16; 17(6):959-968. PubMed ID: 30600291
    [Abstract] [Full Text] [Related]

  • 6. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
    Tronina O, Durlik M, Wawrzynowicz-Syczewska M, Buivydiene A, Katzarov K, Kupcinskas L, Tolmane I, Karpińska E, Pisula A, Karwowska KM, Bolewska B, Jabłkowski M, Rostkowska K, Jakutiene J, Simonova M, Flisiak R.
    Ann Transplant; 2017 Apr 07; 22():199-207. PubMed ID: 28386057
    [Abstract] [Full Text] [Related]

  • 7. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Isakov V, Paduta D, Viani RM, Enejosa JV, Pasechnikov V, Znoyko O, Ogurtsov P, Bogomolov PO, Maevskaya MV, Chen X, Shulman NS.
    Eur J Gastroenterol Hepatol; 2018 Sep 07; 30(9):1073-1076. PubMed ID: 29762255
    [Abstract] [Full Text] [Related]

  • 8. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
    Steiner S, Bucsics T, Schwabl P, Mandorfer M, Scheiner B, Aichelburg MC, Grabmeier-Pfistershammer K, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T.
    Wien Klin Wochenschr; 2017 Aug 07; 129(15-16):517-526. PubMed ID: 28130599
    [Abstract] [Full Text] [Related]

  • 9. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
    Yu ML, Chen YL, Huang CF, Lin KH, Yeh ML, Huang CI, Hsieh MH, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL.
    J Formos Med Assoc; 2018 Jun 07; 117(6):518-526. PubMed ID: 28662883
    [Abstract] [Full Text] [Related]

  • 10. Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
    Özer Etik D, Suna N, Öcal S, Selçuk H, Dağlı Ü, Çolak T, Hilmioğlu F, Boyacıoğlu AS, Haberal M.
    Exp Clin Transplant; 2019 Feb 07; 17(1):52-58. PubMed ID: 30719954
    [Abstract] [Full Text] [Related]

  • 11. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
    Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A, ABACUS study group, AIFA team.
    Lancet Gastroenterol Hepatol; 2017 Jun 07; 2(6):427-434. PubMed ID: 28497758
    [Abstract] [Full Text] [Related]

  • 12. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
    Khatri A, Mensing S, Podsadecki T, Awni W, Menon R, Dutta S.
    Clin Drug Investig; 2016 Aug 07; 36(8):625-35. PubMed ID: 27153823
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
    Janczewska E, Zarębska-Michaluk D, Berak H, Piekarska A, Gietka A, Dybowska D, Mazur W, Belica-Wdowik T, Dobracki W, Tudrujek-Zdunek M, Deroń Z, Buczyńska I, Sitko M, Czauż-Andrzejuk A, Lorenc B, Białkowska-Warzecha J, Citko J, Laurans Ł, Jaroszewicz J, Socha Ł, Tronina O, Adamek B, Horban A, Halota W, Baka-Ćwierz B, Tomasiewicz K, Simon K, Garlicki A, Wawrzynowicz-Syczewska M, Flisiak R.
    BMC Infect Dis; 2018 Nov 16; 18(1):580. PubMed ID: 30445916
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL, Crespo J, Rincón D, Ruiz-Antorán B, Fernandez I, Perelló C, Gea F, Lens S, García-Samaniego J, Sacristán B, García-Eliz M, Llerena S, Pascasio JM, Turnes J, Torras X, Morillas RM, Llaneras J, Serra MA, Diago M, Rodriguez CF, Ampuero J, Jorquera F, Simon MA, Arenas J, Navascues CA, Bañares R, Muñoz R, Albillos A, Mariño Z, Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group.
    J Hepatol; 2017 Jun 16; 66(6):1138-1148. PubMed ID: 28189751
    [Abstract] [Full Text] [Related]

  • 15. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F, Pradat P, Virlogeux V, Zoulim F.
    Dig Dis; 2015 Jun 16; 33(4):613-23. PubMed ID: 26159282
    [Abstract] [Full Text] [Related]

  • 16. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
    Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Hu YB, Podsadecki T, Bernstein B.
    Gastroenterology; 2014 Aug 16; 147(2):359-365.e1. PubMed ID: 24818763
    [Abstract] [Full Text] [Related]

  • 17. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
    Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F.
    J Hepatol; 2016 Feb 16; 64(2):301-307. PubMed ID: 26476290
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
    Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, Morillas RM, Hall C, Mobashery N, Redman R, Pilot-Matias T, Vilchez RA, Hézode C.
    Gastroenterology; 2015 Oct 16; 149(4):971-80.e1. PubMed ID: 26170136
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
    Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB.
    Aliment Pharmacol Ther; 2018 Jul 16; 48(1):35-43. PubMed ID: 29797514
    [Abstract] [Full Text] [Related]

  • 20. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
    Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B.
    N Engl J Med; 2014 Apr 24; 370(17):1594-603. PubMed ID: 24720703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.